A phase II trial examined the combination of Seribantumab with Erlotinib or Erlotinib as a monotherapy in advanced, EGFR wild-type non-small-cell lung cancer who had not received any TKIs targeting EGFR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.